Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.

@article{Webster2006TargetOR,
  title={Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.},
  author={Angela C Webster and Vincent W S Lee and Jeremy Robert Chapman and Jonathan C Craig},
  journal={Transplantation},
  year={2006},
  volume={81 9},
  pages={1234-48}
}
BACKGROUND Target of rapamycin inhibitors (TOR-I) have a novel mode of action but uncertain clinical role. We performed a systematic review of randomized trials where immunosuppressive regimens containing TOR-I were compared with other regimens as initial therapy for kidney transplant recipients. METHODS Databases (inception, June 2005) and conference proceedings (1996-2005) were searched. Two independent reviewers assessed trials for eligibility and quality. Results at 1 year, are expressed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 107 extracted citations

KDIGO clinical practice guideline for the care of kidney transplant recipients.

SUPPORTING TABLES
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2009
View 9 Excerpts
Highly Influenced

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.

Clinical journal of the American Society of Nephrology : CJASN • 2016
View 4 Excerpts
Highly Influenced

Immunosuppressive Drugs in Kidney Transplantation

Drugs • 2009
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…